Product References
Alpha-synuclein-associated changes in PINK1-PRKN-mediated mitophagy are disease context dependent.
Brain pathology (Zurich, Switzerland)
Hou X,Chen TH,Koga S,Bredenberg JM,Faroqi AH,Delenclos M,Bu G,Wszolek ZK,Carr JA,Ross OA,McLean PJ,Murray ME,Dickson DW,Fiesel FC,Springer W
MA1-90346 was used in Immunohistochemistry to suggest that pS65-Ub may be useful as a biomarker to discriminate different synucleinopathies and may serve as a potential therapeutic target for Lewy body disease.
Fri Sep 01 00:00:00 EDT 2023
Human pericytes degrade diverse α-synuclein aggregates.
PloS one
Dieriks BV,Highet B,Alik A,Bellande T,Stevenson TJ,Low V,Park TI,Correia J,Schweder P,Faull RLM,Melki R,Curtis MA,Dragunow M
MA1-90346 was used in Dot Blot, ELISA, Immunohistochemistry (Frozen), Immunohistochemistry (Paraffin), Western Blot, Immunocytochemistry to highlight the role brain vasculature may play in reducing α-syn aggregate burden in Parkinson's disease.
Tue Nov 22 00:00:00 EST 2022
Human pericytes degrade diverse α-synuclein aggregates.
PloS one
Dieriks BV,Highet B,Alik A,Bellande T,Stevenson TJ,Low V,Park TI,Correia J,Schweder P,Faull RLM,Melki R,Curtis MA,Dragunow M
MA1-90346 was used in Dot Blot, ELISA, Immunohistochemistry (Frozen), Immunohistochemistry (Paraffin), Western Blot, Immunocytochemistry to highlight the role brain vasculature may play in reducing α-syn aggregate burden in Parkinson's disease.
Tue Nov 22 00:00:00 EST 2022
α-synuclein buildup is alleviated via ESCRT-dependent endosomal degradation brought about by p38MAPK inhibition in cells expressing p25α.
The Journal of biological chemistry
Borland H,Rasmussen I,Bjerregaard-Andersen K,Rasmussen M,Olsen A,Vilhardt F
MA1-90346 was used in Sample Preparation to suggest that under conditions of autophagolysosomal malfunction, the uninterrupted endosomal pathway offers a possibility to achieve disease-associated protein degradation.
Tue Nov 01 00:00:00 EDT 2022
Lipase regulation of cellular fatty acid homeostasis as a Parkinson's disease therapeutic strategy.
NPJ Parkinson's disease
Fanning S,Cirka H,Thies JL,Jeong J,Niemi SM,Yoon J,Ho GPH,Pacheco JA,Dettmer U,Liu L,Clish CB,Hodgetts KJ,Hutchinson JN,Muratore CR,Caldwell GA,Caldwell KA,Selkoe D
MA1-90346 was used in Western Blotting to identify the rate-limiting lipase enzyme, LIPE, as a candidate target.
Thu Jun 09 00:00:00 EDT 2022
The Parkinson's disease protein alpha-synuclein is a modulator of processing bodies and mRNA stability.
Cell
Hallacli E,Kayatekin C,Nazeen S,Wang XH,Sheinkopf Z,Sathyakumar S,Sarkar S,Jiang X,Dong X,Di Maio R,Wang W,Keeney MT,Felsky D,Sandoe J,Vahdatshoar A,Udeshi ND,Mani DR,Carr SA,Lindquist S,De Jager PL,Bartel DP,Myers CL,Greenamyre JT,Feany MB,Sunyaev SR,Chung CY,Khurana V
MA1-90346 was used in Dot Blot, ELISA, Immunohistochemistry (Frozen), Immunohistochemistry (Paraffin), Western Blot to show that αS directly modulates processing bodies (P-bodies), membraneless organelles that function in mRNA turnover and storage.
Thu Jun 09 00:00:00 EDT 2022
Clinicopathological Staging of Dynamics of Neurodegeneration and Neuronal Loss in Alzheimer Disease.
Journal of neuropathology and experimental neurology
Wegiel J,Flory M,Kuchna I,Nowicki K,Ma SY,Wegiel J,Badmaev E,Leon M,Wisniewski T,Reisberg B
MA1-90346 was used in Immunohistochemistry to establish the pattern of neurodegeneration, and the severity and rate of neuronal loss in mild cognitive impairment/mild Alzheimer's disease.
Fri Jan 01 00:00:00 EST 2021
Altered conformation of α-synuclein drives dysfunction of synaptic vesicles in a synaptosomal model of Parkinson's disease.
Cell reports
Fonseca-Ornelas L,Viennet T,Rovere M,Jiang H,Liu L,Nuber S,Ericsson M,Arthanari H,Selkoe DJ
MA1-90346 was used in Western Blot to conclude that the synaptic microenvironment is necessary for αSyn to reach its native conformations and establish a physiological interaction network.
Tue Jul 06 00:00:00 EDT 2021
Altered conformation of α-synuclein drives dysfunction of synaptic vesicles in a synaptosomal model of Parkinson's disease.
Cell reports
Fonseca-Ornelas L,Viennet T,Rovere M,Jiang H,Liu L,Nuber S,Ericsson M,Arthanari H,Selkoe DJ
MA1-90346 was used in Western Blot to conclude that the synaptic microenvironment is necessary for αSyn to reach its native conformations and establish a physiological interaction network.
Tue Jul 06 00:00:00 EDT 2021
Establishment of a human induced pluripotent stem cell neuronal model for identification of modulators of A53T α-synuclein levels and aggregation.
PloS one
Vajhøj C,Schmid B,Alik A,Melki R,Fog K,Holst B,Stummann TC
Published figure using alpha Synuclein monoclonal antibody (Product # MA1-90346) in Western Blot
Tue Jan 11 00:00:00 EST 2022
Nilotinib Fails to Prevent Synucleinopathy and Cell Loss in a Mouse Model of Multiple System Atrophy.
Movement disorders : official journal of the Movement Disorder Society
Lopez-Cuina M,Guerin PA,Canron MH,Delamarre A,Dehay B,Bezard E,Meissner WG,Fernagut PO
MA1-90346 was used in Western Blotting to suggest that partial inhibition of c-Abl and reduction of α-synuclein phosphorylation at tyrosine 39 may not be a relevant target for MSA.
Wed Jul 01 00:00:00 EDT 2020
A prolyl oligopeptidase inhibitor, KYP-2047, reduces α-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease.
British journal of pharmacology
Myöhänen TT,Hannula MJ,Van Elzen R,Gerard M,Van Der Veken P,García-Horsman JA,Baekelandt V,Männistö PT,Lambeir AM
MA1-90346 was used in immunocytochemistry, immunohistochemistry, and western blot to study the reduction in the levels of alpha-synuclein protein and aggregation by a prolyl peptidase inhibitor in various models of Parkinson's disease
Fri Jun 01 00:00:00 EDT 2012
A prolyl oligopeptidase inhibitor, KYP-2047, reduces α-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease.
British journal of pharmacology
Myöhänen TT,Hannula MJ,Van Elzen R,Gerard M,Van Der Veken P,García-Horsman JA,Baekelandt V,Männistö PT,Lambeir AM
MA1-90346 was used in immunocytochemistry, immunohistochemistry, and western blot to study the reduction in the levels of alpha-synuclein protein and aggregation by a prolyl peptidase inhibitor in various models of Parkinson's disease
Fri Jun 01 00:00:00 EDT 2012
A prolyl oligopeptidase inhibitor, KYP-2047, reduces α-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease.
British journal of pharmacology
Myöhänen TT,Hannula MJ,Van Elzen R,Gerard M,Van Der Veken P,García-Horsman JA,Baekelandt V,Männistö PT,Lambeir AM
MA1-90346 was used in immunocytochemistry, immunohistochemistry, and western blot to study the reduction in the levels of alpha-synuclein protein and aggregation by a prolyl peptidase inhibitor in various models of Parkinson's disease
Fri Jun 01 00:00:00 EDT 2012